AI Article Synopsis

  • In Denmark, a mandatory shift from the original adalimumab to two biosimilars, GP2017 (Hyrimoz) and SB5 (Imraldi), occurred in 2018, prompting a study to compare their effectiveness for treating rheumatoid arthritis, psoriatic arthritis, and axial spondyloarthritis.
  • An observational study using the DANBIO registry was conducted, analyzing treatment retention and remission rates through statistical methods, ultimately including 1318 patients who switched to either GP2017 or SB5.
  • Results showed that GP2017 had a lower withdrawal risk and higher 6-month remission rates compared to SB5, although conclusions may be influenced by factors like differences in patient groups or variations in the

Article Abstract

Objectives: In 2018, a nationwide mandatory switch from originator to biosimilar adalimumab was conducted in Denmark. The available biosimilar was GP2017 (Hyrimoz) in Eastern regions and SB5 (Imraldi) in Western regions. We aimed to assess the comparative effectiveness of GP2017 versus SB5 in patients with rheumatoid arthritis (RA)/psoriatic arthritis (PsA)/axial spondyloarthritis (AxSpA).

Methods: Observational cohort study based on the DANBIO registry with geographical cluster pseudo-randomisation, analysed by emulating a randomised clinical trial. Main outcome was adjusted 1-year treatment retention (Cox regression). Furthermore, 6 months' remission rates (logistic regression), reasons for withdrawal and back-switching to originator were investigated (overall and stratified by indication).

Results: Overall, of 1570 eligible patients, 1318 switched and were included (467 RA/321 PsA/530 AxSpA); 623 (47%) switched to GP2017, 695 (53%) to SB5. Baseline characteristics of the two clusters were largely similar, but some differences in registration practice were observed. The combined 1-year retention rate for the two biosimilars was 89.5%. Compared with SB5, estimated risk of withdrawal for GP2017 was lower (HR 0.60; 95% CI 0.42 to 0.86) and 6 months' remission rate was higher (OR 1.72; 95% CI 1.25 to 2.37). Stratified analyses gave similar results (statistically significant for RA). During 1 year, 8.5% and 12.9% withdrew GP2017 and SB5, respectively (primarily lack of effect and adverse events), of whom 48 patients (3.6%) back-switched.

Conclusion: This head-to-head comparison of GP2017 versus SB5 following a mandatory switch from the originator indicated differences in effectiveness in routine care. This may reflect a true difference, but other explanations, for example, differences in excipients, differences between clusters and residual confounding cannot be ruled out.

Download full-text PDF

Source
http://dx.doi.org/10.1136/annrheumdis-2021-219951DOI Listing

Publication Analysis

Top Keywords

switch originator
12
comparative effectiveness
8
emulating randomised
8
randomised clinical
8
clinical trial
8
mandatory switch
8
gp2017 versus
8
versus sb5
8
gp2017
6
sb5
6

Similar Publications

Want AI Summaries of new PubMed Abstracts delivered to your In-box?

Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!